

AbbVie is quietly crushing the market while broader indexes bleed red.
It surged 3.43% yesterday, and the move was purely company-specific—not a sector or macro fluke. The successful debt offering to fund the Apogee acquisition, combined with raised full-year guidance and bullish analyst price targets, is the real catalyst. Big money is clearly piling in, too—net inflow hit $30M yesterday with major institutions stepping up. Sure, the RSI is sitting in pretty overbought territory, so a short-term pullback wouldn't surprise anyone, but the long-term fundamentals still look rock solid with their immunology pipeline extending well.